Abstract: A compound comprising a first ligand LA of Formula I, in provided. In Formula I, moiety X is a fused multicyclic ring system comprising two or more rings; rings A and B are independently a 5- or 6-membered carbocyclic or heterocyclic ring; Z1, Z2, and Z3 are each C or N; K3 and K4 are each a direct bond, O, or S; each RA, RB, and RX is hydrogen or a substituent; and at least one of the following conditions is true: (1) ring B is partially or fully deuterated, or (2) at least one RB is an aryl or heteroaryl group that is partially or fully deuterated. The ligand LA is coordinated to a metal M through the dashed lines, and any two substituents except an RX with an RB may be joined to form a ring. Formulations, OLEDs, and consumer products containing these compounds are also provided.

Abstract: Provided is a compound comprising a first ligand LA of

Abstract: Heteroleptic compounds having a structure of Ir(LA)p(LB)q(LC)r, where LB and LC are different bidentate ligands, p is 1 or 2, q is 1 or 2, r is 0, 1, or 2, and ligand LA has a structure of Formula I, In Formula I, moiety B is a monocyclic or polycyclic fused ring system; each of X1 to X6 is C or N; each RA, RB, and RC is independently a hydrogen or a general substituent; at least one RB comprises a partially or fully deuterated alkyl or cycloalkyl group; if moiety B is phenyl, at least two adjacent RC substituents are fused to form a ring, with the proviso that at least one LB or LC is present and is not a phenylpyridine-based ligand. Formulations, OLEDs, and consumer products containing the same are also disclosed.

Abstract: A compound having a formula (LA)mIr(LB)3?m having a structure selected from is disclosed. In the structures of formula (LA)mIr(LB)3-m, m is 1 or 2, R1, R2, R3, R4, and R5 are each independently selected from hydrogen, deuterium, C1 to C6 alkyl, C1 to C6 cycloalkyl, and partially or fully deuterated variants thereof, and partially or fully fluorinated variants thereof, and, R6 is selected from C1 to C6 alkyl, C1 to C6 cycloalkyl, and partially or fully deuterated variants thereof, and partially or fully fluorinated variants thereof.

Abstract: A composition formed of a mixture of two compounds having similar thermal evaporation properties that are pre-mixed into an evaporation source that can be used to co-evaporate the two compounds into an emission layer in OLEDs via vacuum thermal evaporation process is disclosed.

Abstract: Organometallic compounds comprising an imidazole carbene ligand having a N-containing ring fused to the imidazole ring are provided. In particular, the N-containing ring fused to the imidazole ring may contain one nitrogen atom or more than one nitrogen atom. These compounds may demonstrate high photoluminescent (PL) efficiency, Gaussian emission spectra, and/or short excited state lifetimes. These materials may be especially useful as blue phosphorescent emitters.

Abstract: A compound of: is disclosed. In Formula III, ring B and ring C are each independently a 5 or 6-membered carbocyclic or heterocyclic ring; A-B represents a bonded pair of carbocyclic or heterocyclic rings coordinated to a metal M via a nitrogen atom in ring A and an sp2 hybridized atom in ring B; A-C represents a bonded pair of carbocyclic or heterocyclic rings; M is a metal having an atomic number greater than 40; L? is a monoanionic bidentate ligand; m is the oxidation state of the metal M; and n is at least 1.

Abstract: A compound comprising a first ligand LA of Formula I is described. In Formula I, X1 and X6 to X10 are each independently C or N; X2 is CR1? or N; X3 is CR1 or N; X4 is CR2 or N; X5 is CR3 or N; each R1, R2, R3, RA, RB, and RC is independently a hydrogen or a General Substituent; any two substituents may be joined or fused to form a ring; at least one of R1?, R1, R2, and R3 is a partially or fully deuterated alkyl or cycloalkyl group; at least one pair of RC are joined or fused to form a 5-membered or 6-membered ring. Formulations, OLEDs, and consumer products comprising the compound are also described.

Abstract: A compound, Ir(LA)m(LB)3-m, having a structure of Formula I, is provided. In Formula I, each of moiety A and moiety C is independently a 5- or 6-membered ring or a polycyclic fused ring system comprising 5- or 6-membered rings; moiety B is a 5-membered heterocyclic ring; Z1, Z2, and Z3 are C or N; m is 1 or 2; at least one of R1, R2, R3, R4 has a structure of Formula II, or is a 5-membered heterocyclic ring; each of X1, X2, X3, X4, and X5 is CR or N; each of R1, R2, R3, R4, RA, RB, RC, and R is hydrogen or a General Substituent; at least one of R1a, R2a, R3a, R4a, R5a is cycloalkyl, alkyl, silyl, germyl, deuterated variants thereof, fluorinated variants thereof, and combinations thereof. Formulations, OLEDs, and consumer products containing the compound are also provided.

Abstract: A compound including a first ligand LA of Formula I, is disclosed. In Formula I, ring B is a 5- or 6-membered ring; X1, X2, and X3 are each CRA or N; R is a 5- or 6-membered carbocyclic or heterocyclic ring, which can be further fused or substituted; and (1) when ring B is an unfused 6-membered ring, X1 and X2 are N, and X3 is C; and (2) when ring B is a fused 6-membered ring, ring B has the structure of Formula II, In this structure, the wavy line indicates the point of connection to ring A; Q1 to Q6 are each C or N; and, when proviso (2) applies, (I) at least one of X1, X2, and X3 is N; or (II) R is two or more fused or unfused 5- or 6-membered carbocyclic or heterocyclic rings, or (III) at least ring A or R is substituted with a partially or fully deuterated alkyl or partially or fully deuterated cycloalkyl group.

Abstract: A heteroleptic compound having a Formula Ir(LA)m(LB)3-m, having a structure of Formula I is disclosed. In Formula I, m is 1 or 2; moieties A, C, and D are each independently monocyclic rings or polycyclic fused ring structures; each R1, R2, RA, RB, RC, RD, and RE is independently hydrogen or a substituent; if moiety A is a monocyclic 6-membered ring, then the RA para to N of ring A is not an aryl group; at least one of R1 and R2 is selected from the group consisting of aryl, heteroaryl, cycloalkyl, heterocycloalkyl, and combinations thereof; and adjacent substituents can be joined to form a ring. OLEDs, consumer products, and formulations including the heteroleptic compound are also disclosed.

Abstract: The present disclosure provides for an organic electroluminescent device (OLED) including an anode; a cathode; and an emissive layer, disposed between the anode and the cathode. The emissive layer includes a phosphorescent dopant, a first host, and a second host, wherein the first host transports holes, the second host transports electrons, and the first host is fully or partially deuterated. Consumer products that include the OLED are also provided.

Abstract: Heteroleptic compounds having a Formula Ir(LA)m(LB)3-m, having the structure of Formula I or Formula II, are described. In Formula I and Formula II, moiety B is a polycyclic fused ring structure comprising at least four rings; ring C is a 5- or 6-membered aromatic ring; moieties D and E are independently a monocyclic or polycyclic fused ring structure; Z1 and Z2 are each independently C or N; each RA, RB, RC, RD, and RE is hydrogen or a General Substituent; and when ring C is a phenyl ring, RC collectively comprises two or more C atoms. Formulations, OLEDs, and consumer products incorporating the compounds are also described.

Abstract: A novel compound is disclosed which includes a ligand LA of Formula II, wherein: ring B is independently a 5-membered or 6-membered carbocyclic or heterocyclic ring; X1 to X4 are each independently selected from the group consisting of C, N, and CR; at least one pair of adjacent X1 to X4 are each C and fused to Formula V ?where indicated by “”; X5 to X12 are each independently C or N; the maximum number of N within a ring is two; Z and Y are each independently selected from the group consisting of O, S, Se, NR?, CR?R?, SiR?R?, and GeR?R?; RB and RC each independently represents zero, mono, or up to a maximum allowed substitutions to its associated ring; each of RB, RC, R, R?, and R? is independently hydrogen or a substituent selected from the group consisting of deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile,

Abstract: A phosphorescent metal complexes containing a ligand LA having the formula selected from is disclosed.

Abstract: A compound having a structure of is disclosed. In these formulas, each R1, R2, and R3 is independently selected from hydrogen, alkyl, and aryl; at least one of R1 and R2 is a branched alkyl containing at least 4 carbon atoms, where the branching occurs at a position further than the benzylic position; where R1 and R3 are mono-, di-, tri-, tetra-, or no substitutions; and R2 is mono-, di-, or no substitutions. Heteroleptic iridium complexes including such compounds, and devices including such compounds are also disclosed.

Abstract: Compounds containing indolocarbazole compounds of Formula I or Formula II comprising terphenyl groups and compounds of Formula III comprising triazine groups are disclosed in this application. These compounds are useful for application in organic electroluminescent devices.

Abstract: Provided are organometallic compounds that includes a ligand LA of Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

Abstract: A compound of: is disclosed. In Formula IV, ring B and ring C are each independently a 5 or 6-membered carbocyclic or heterocyclic ring; A-B represents a bonded pair of carbocyclic or heterocyclic rings coordinated to a metal M via a nitrogen atom in ring A and an sp2 hybridized atom in ring B; A-C represents a bonded pair of carbocyclic or heterocyclic rings; M is a metal having an atomic number greater than 40; L? is a monoanionic bidentate ligand; m is the oxidation state of the metal M; and n is at least 1.

Abstract: Provided are organometallic compounds having a structure of Also provided are formulations comprising these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.